Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Journal article

Temesgen Z. et al, (2022), The lancet respiratory medicine, 10, 237 - 246

S49 C-reactive protein as a biomarker for improved efficacy of lenzilumab in Covid-19 patients: results from the LIVE-AIR trial

Conference paper

Temesgen Z. et al, (2021), Developing treatments for covid-19

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL

Journal article

TEMESGEN Z. et al, (2021), Chest, 160, A2522 - A2524

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia

Journal article

Temesgen Z. et al, (2020), Mayo clinic proceedings, 95, 2382 - 2394

An effective mouse model for adoptive cancer immunotherapy targeting neoantigens

Journal article

Hanada K-I. et al, (2019), Jci insight, 4